U.S. Markets closed

Illumina Stock Appears To Be Modestly Overvalued

·4 min read

- By GF Value

The stock of Illumina (NAS:ILMN, 30-year Financials) gives every indication of being modestly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $450.67 per share and the market cap of $65.8 billion, Illumina stock appears to be modestly overvalued. GF Value for Illumina is shown in the chart below.


Illumina Stock Appears To Be Modestly Overvalued
Illumina Stock Appears To Be Modestly Overvalued

Because Illumina is relatively overvalued, the long-term return of its stock is likely to be lower than its business growth, which averaged 5.6% over the past three years and is estimated to grow 10.65% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Illumina has a cash-to-debt ratio of 1.61, which is in the middle range of the companies in the industry of Medical Diagnostics & Research. The overall financial strength of Illumina is 6 out of 10, which indicates that the financial strength of Illumina is fair. This is the debt and cash of Illumina over the past years:

Illumina Stock Appears To Be Modestly Overvalued
Illumina Stock Appears To Be Modestly Overvalued

It poses less risk to invest in profitable companies, especially those that have demonstrated consistent profitability over the long term. A company with high profit margins is also typically a safer investment than one with low profit margins. Illumina has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $3.5 billion and earnings of $4.28 a share. Its operating margin is 16.82%, which ranks better than 73% of the companies in the industry of Medical Diagnostics & Research. Overall, GuruFocus ranks the profitability of Illumina at 8 out of 10, which indicates strong profitability. This is the revenue and net income of Illumina over the past years:

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Illumina is 5.6%, which ranks in the middle range of the companies in the industry of Medical Diagnostics & Research. The 3-year average EBITDA growth rate is -4%, which ranks worse than 73% of the companies in the industry of Medical Diagnostics & Research.

One can also evaluate a company's profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely creating value for its shareholders. During the past 12 months, Illumina's ROIC is 11.08 while its WACC came in at 6.59.

Overall, The stock of Illumina (NAS:ILMN, 30-year Financials) shows every sign of being modestly overvalued. The company's financial condition is fair and its profitability is strong. Its growth ranks worse than 73% of the companies in the industry of Medical Diagnostics & Research. To learn more about Illumina stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.